As a psychedelic therapy developer, Compass Pathways (NASDAQ: CMPS) is on the cutting edge of innovation in treating mood disorders. That makes it an exciting, if quite risky, investment.

But a lot of that risk burden could be alleviated soon, thanks to a pair of upcoming catalysts. If that happens, the stock has a high chance of skyrocketing. Let's take a moment to understand both of these two looming key events.

Compass' lead program is called COMP360, and for now it's being investigated in late-stage clinical trials for its utility in helping people with treatment-resistant depression (TRD), post-traumatic stress disorder (PTSD), and anorexia.

Continue reading

Source Fool.com